FDA approves Kisqali and Kisqali Femara Co-Pack
WEB5 days ago · On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack ...
What are the benefits of taking Kisqali and Femara together? - Drugs.com
WEBTaking Kisqali and Femara together can benefit patients with specific types of breast cancer because the medications work in different ways. Kisqali blocks the growth of cancer cells, while Femara reduces the amount of estrogen in the body that can fuel cancer growth.
Kisqali Approved for HR+, HER2- Early Breast Cancer
WEB4 days ago · The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive,...
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2
WEB4 days ago · READ MORE: FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer. In terms of specific subgroup data, the iDFS rates among patients with stage 2 disease were 94.4% versus 92.7% at three years with a change of 1.7% and 93.9% versus 89.6% at four years with Kisqali /NSAI versus NSAI alone with a …
FDA Approves Ribociclib With an Aromatase Inhibitor and …
WEBAdditionally, FDA approved the ribociclib and letrozole co-pack (Kisqali ® Femara ® Co-Pack) for the same indication. Efficacy of ribociclib with a nonsteroidal aromatase inhibitor (NSAI) was evaluated in NATALEE (NCT03701334), a randomized, open-label, multicenter trial involving 5,101 adults with HR-positive, HER2-negative early breast cancer.
Adding Kisqali to Femara Improves Overall Survival for …
WEBAdding Kisqali to Femara as a treatment for advanced-stage hormone-receptor-positive HER2-negative breast cancer in women improved overall survival.
FDA Approves Adjuvant Ribociclib (Kisqali) Plus an Aromatase …
WEB4 days ago · On Sept. 17, the U.S. Food and Drug Administration (FDA) approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor for adults with hormone receptor (HR)-positive, HER2-negative stage II and stage III early breast cancer who are at a high risk for recurrence. The agency also approved the ribociclib and letrozole co-pack (Kisqali Femara Co-Pack) for the same indication.
Ribociclib Improves Survival in Advanced Breast Cancer
WEBOct 6, 2021 · In the clinical trial, called MONALEESA-2, women treated with the CDK4/6 inhibitor ribociclib (Kisqali) and the hormone-blocking drug letrozole (Femara) as their initial treatment for advanced breast cancer lived approximately 1 year longer overall than women treated with letrozole alone.
FDA Approves Ribociclib With an Aromatase Inhibitor in Early …
WEB5 days ago · The FDA has approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor (AI) in hormone receptor (HR)-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. This indication includes patients with node-negative disease. Data from the phase 3 NATALEE trial (NCT03701334) support …
KISQALI FEMARA Co-Pack | KISQALI® (ribociclib) | HCP
WEBThe KISQALI FEMARA Co-Pack is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.